Clinical Trials
57 trialsNCT03570827 2026-05-26
Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy
Mayo Clinic
Phase 2 Completed
NCT03987386 2026-05-20
Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase 3 Active not recruiting
NCT04423211 2026-05-15
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT04947254 2026-05-15
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04134260 2026-05-07
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
NRG Oncology
Phase 3 Recruiting
NCT05946213 2026-05-07
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NRG Oncology
Phase 3 Recruiting
NCT03217747 2026-05-05
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT04513717 2026-05-04
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NRG Oncology
Phase 3 Active not recruiting
NCT06378866 2026-04-20
DIVINE
Mayo Clinic
Phase 2 Recruiting
NCT06235697 2026-04-14
ASCENDE-SBRT
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT06244004 2026-03-30
FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
Northwestern University
Phase 2 Recruiting
NCT06171269 2026-03-04
Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life
University of Chicago
Phase NA Recruiting
NCT06650579 2026-02-24
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
Emory University
Phase 3 Recruiting
NCT06037863 2026-02-23
Evaluation of the Impact of Empty Versus Full Bladder in Patients With Prostate Cancer, RELIEF Trial
Mayo Clinic
Phase NA Active not recruiting
NCT03861676 2026-02-13
Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase EARLY_PHASE1 Recruiting
NCT06625034 2026-02-10
Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer
Mayo Clinic
Phase 3 Recruiting
NCT04478279 2026-02-09
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Sapience Therapeutics
Phase 1/2 Active not recruiting
NCT07202247 2026-02-04
Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial
City of Hope Medical Center
Phase 2 Recruiting
NCT06205316 2026-01-20
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
Mayo Clinic
Phase 3 Recruiting
NCT03371719 2026-01-14
Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial
NRG Oncology
Phase 2 Active not recruiting
NCT02023463 2025-11-25
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
Thomas Jefferson University
Phase 1 Active not recruiting
NCT05805371 2025-11-19
PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT06528210 2025-09-23
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Withdrawn
NCT03889119 2025-09-15
Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer
Hoag Memorial Hospital Presbyterian
Phase NA Active not recruiting
NCT05230251 2025-09-12
ROADSTER
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 1/2 Completed
NCT03678025 2025-09-11
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
SWOG Cancer Research Network
Phase 3 Recruiting
NCT00924027 2025-09-05
A Study of Patients Receiving High-Dose Rate Brachytherapy
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01492972 2025-09-04
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
Proton Collaborative Group
Phase 3 Recruiting
NCT01508390 2025-06-26
Hypofractionated Stereotactic Body Radiation Therapy as a Boost to the Prostate
Boston Medical Center
Phase NA Active not recruiting
NCT04249154 2025-06-25
PROMPT
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase 2 Recruiting
NCT01342367 2025-06-10
Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer
University of Chicago
Phase NA Active not recruiting
NCT02184533 2024-05-28
Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer
Stanford University
Phase 1 Completed
NCT06129851 2023-11-13
Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer
University of Kansas Medical Center
Phase 2 Not yet recruiting
NCT03649841 2023-10-26
Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
University of Washington
Phase 2 Terminated
NCT03043807 2023-02-16
A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT05717582 2023-02-08
CHAMPION
Fudan University
Phase 2 Not yet recruiting
NCT04457245 2023-01-17
PSMA-dRT
Jonsson Comprehensive Cancer Center
Phase 3 Terminated
NCT00860652 2022-11-18
RAVES
Trans Tasman Radiation Oncology Group
Phase NA Active not recruiting
NCT02064036 2022-10-18
CCRO025
University of California, Davis
Phase 1 Completed
NCT02716974 2022-08-04
oligo-mets
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00116142 2022-01-11
Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer
Dana-Farber Cancer Institute
Phase 3 Completed
NCT01833208 2021-08-05
Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T
Roswell Park Cancer Institute
Phase NA Completed
NCT02229734 2021-06-04
FASTR-2
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 2 Completed
NCT04585932 2021-01-20
Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT02064582 2020-10-12
Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT00124917 2019-09-13
Phase I Study of Intensity Modulated Radiation Therapy for Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT00214422 2019-07-19
Intensity Modulated Radiation Therapy for Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase EARLY_PHASE1 Completed
NCT01091883 2019-03-13
Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma
InSightec
Phase NA Completed
NCT01303705 2018-08-29
Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer
Providence Health & Services
Phase 1 Completed
NCT01677845 2017-08-28
Hypo-Fractionated Radiation Therapy for Localized Prostate Cancer
NYU Langone Health
Phase 1 Terminated